Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compassionate Use Program For the Treating Severely Ill Patients of COVID-19 With Remdesivir

Next Previous
Trial Profile

Compassionate Use Program For the Treating Severely Ill Patients of COVID-19 With Remdesivir

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 15 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remdesivir (Primary)
  • Indications COVID 2019 infections; Severe acute respiratory syndrome
  • Focus Adverse reactions; Expanded access; Registrational; Therapeutic Use
  • Sponsors Gilead Sciences

Most Recent Events

  • 10 Jul 2020 According to an Gilead Sciences media release, data from this study were presented at the Virtual COVID-19 Conference as part of the 23rd International AIDS Conference (AIDS 2020: Virtual).
  • 10 Jul 2020 Results presented in a Gilead Sciences media release.
  • 07 May 2020 According to an Gilead Sciences media release, the Japanese Ministry of Health, Labour and Welfare (MHLW) approval is based on clinical data from the U.S. National Institute of Allergy and Infectious Diseases's global Phase 3 trial, the company's Phase 3 SIMPLE trial in patients with severe manifestations of COVID-19, and available data from company's compassionate use program, including patients in Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top